Experimental feature

Listen to this article

Experimental feature

Drugmaker Merck & Co said Thursday it will take an after-tax charge of $1.9bn in connection with a research programme for a drug being eyed to treat hepatitis C.

The drug – MK-3682, uprifosbuvir – was obtained by Merck in its 2014 acquisition of Idenix Pharmaceuticals, which it snapped up in hopes of bolstering its position in the race to develop a new generation of hepatitis C treatments.

Merck said in a regulatory filing on Thursday that it “determined that recent changes to the product profile, as well as changes to its expectations for pricing and the market opportunity, taken together constituted a triggering event that required the Company to evaluate the uprifosbuvir intangible asset for impairment”.

As a result, Merck said it was recognising a pre-tax impairment charge of $2.9bn, which shakes out to $1.9bn after taxes and will be reflected in its 2016 results.

The company’s previously reported earnings per share were lowered from 42 cents to a loss of 22 cents, with full-year 2016 earnings per share reduced from $2.04 to $1.41. The revisions reflect the impact of the charge, which was partly offset by other adjustments, the company said.

Copyright The Financial Times Limited 2017. All rights reserved.

Follow the topics mentioned in this article

Follow the authors of this article

Comments have not been enabled for this article.